Next Article in Journal
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma
Previous Article in Journal
Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada
 
 
Review

Article Versions Notes

Curr. Oncol. 2025, 32(3), 143; https://doi.org/10.3390/curroncol32030143
Action Date Notes Link
article xml file uploaded 28 February 2025 09:50 CET Original file -
article xml uploaded. 28 February 2025 09:50 CET Update -
article pdf uploaded. 28 February 2025 09:50 CET Version of Record https://www.mdpi.com/1718-7729/32/3/143/pdf-vor
article html file updated 28 February 2025 09:52 CET Original file -
article xml file uploaded 4 March 2025 08:18 CET Update -
article xml uploaded. 4 March 2025 08:18 CET Update https://www.mdpi.com/1718-7729/32/3/143/xml
article pdf uploaded. 4 March 2025 08:18 CET Updated version of record https://www.mdpi.com/1718-7729/32/3/143/pdf
article html file updated 4 March 2025 08:21 CET Update https://www.mdpi.com/1718-7729/32/3/143/html
Back to TopTop